Transaction Details

Footnotes

Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. | Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. | Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. | Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. | Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. | Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.